Journal article

Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study

Gregor E Berger, Stephen J Wood, R Mark Wellard, Tina M Proffitt, Mirabel McConchie, G Paul Amminger, Graeme D Jackson, Dennis Velakoulis, Christos Pantelis, Patrick D McGorry

NEUROPSYCHOPHARMACOLOGY | SPRINGERNATURE | Published : 2008

Abstract

Ethyl-eicosapentaenoic acid (E-EPA) is an omega-3 fatty acid that has been used in a range of neuropsychiatric conditions with some benefits. However, its mechanism of action is unknown. Here, we investigate its effects on in vivo brain metabolism in first-episode psychosis (FEP). Proton magnetic resonance spectroscopy at 3 T was performed in the temporal lobes of 24 FEP patients before and after 12 weeks of treatment in the context of a larger double-blind, placebo-controlled E-EPA augmentation study. Treatment group effects for glutathione (F1,12=6.1, p=0.03), and a hemisphere-by-group interaction for glutamine/glutamate (F1,20=4.4, p=0.049) were found. Glutathione increased bilaterally an..

View full abstract